TriLink BioTechnologies社 Stay Ahead of the Curve: Your Monthly Industry News Roundup

Research news

Artificial intelligence applied to mRNA vaccines

Advancements in self-amplifying RNA (saRNA) technology for COVID-19 vaccines showcase promising results, including the approval of the world's first saRNA vaccine in Japan. Studies further highlight the advantages of modified nucleosides in enhancing efficacy and reducing reactogenicity. These findings mark a significant milestone in saRNA-based vaccinology and offer a potential alternative to conventional mRNA.

Read more ➔

In other research news

A universal STING mimic boosts anti-tumor immunity

The blog discusses a new STING mimic called uniSTING, which activates tumor control pathways independently of endogenous STING expression, showing promising anti-tumor efficacy in vivo when delivered via CleanCap^® mRNA encapsulated into lipid nanoparticles

Read more ➔

First mRNA-based approach to endolysin therapy reported

TriLink’s CleanCap^® capping technology and N1-methylpseudouridine are featured in a new Molecular Therapy publication, in which researchers report a novel, mRNA-based approach to endolysin therapy that could be harnessed to tackle the global antibiotic resistance crisis.

Read more ➔

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。